BIOPHYTIS.jpg
BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19
March 22, 2021 03:00 ET | BIOPHYTIS SA
The Company receives a favorable opinion from the DMC on the safety of Sarconeos (BIO101) in the COVA study following first interim analysisPatient enrollment has now reached 97 of the 155 planned for...
BIOPHYTIS.jpg
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd
March 19, 2021 18:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
BIOPHYTIS.jpg
Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors
March 10, 2021 22:08 ET | BIOPHYTIS SA
Legally required documents for shareholders’ votes are available on Biophytis website PARIS and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth...
BIOPHYTIS.jpg
Biophytis Reports 2020 Full Year Results
February 26, 2021 02:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
BIOPHYTIS.jpg
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium
February 17, 2021 02:00 ET | BIOPHYTIS SA
Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory AuthoritiesThese approvals follow the previous authorizations...
BIOPHYTIS.jpg
Biophytis annonce le Règlement-Livraison de son Offre ADS
February 15, 2021 02:00 ET | BIOPHYTIS SA
Montant total de l’offre de 20,1 millions de U.S. dollars dont le règlement-livraison a eu lieu le 12 février 2021.Les ADSs de Biophytis ont été admises aux négociations sur le Nasdaq Capital Market...
BIOPHYTIS.jpg
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
February 15, 2021 02:00 ET | BIOPHYTIS SA
ADS Offering of $20.1 million in gross proceeds closed on February 12, 2021.Biophytis’s ADSs began trading on the Nasdaq Capital Market on February 10, 2021. PARIS and CAMBRIDGE, Mass., Feb. 15,...
BIOPHYTIS.jpg
Biophytis annonce la reprise des négociations de ses actions ordinaires et de ses bons de souscription d’actions sur Euronext Growth
February 10, 2021 09:16 ET | BIOPHYTIS SA
PARIS et CAMBRIDGE, Mass., 10 févr. 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Euronext Growth Paris : ALBPS), société de biotechnologie au stade clinique, spécialisée dans le développement de...
BIOPHYTIS.jpg
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth
February 10, 2021 09:16 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...
BIOPHYTIS.jpg
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
February 10, 2021 04:40 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the...